Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
10 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
TransCode Therapeutics Reports 2023 Results; Provides Business Update
5 Apr 24
8-K
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31 Jan 24
8-K
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
22 Jan 24
8-K
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
16 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
8 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Dec 23
8-K
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
4 Dec 23
8-K
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Nov 23
8-K
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
27 Oct 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
19 Jan 24
S-1/A
IPO registration (amended)
18 Jan 24
S-1/A
IPO registration (amended)
17 Jan 24
S-1
IPO registration
11 Jan 24
424B5
Prospectus supplement for primary offering
1 Dec 23
424B5
Prospectus supplement for primary offering
26 Oct 23
424B4
Prospectus supplement with pricing info
27 Sep 23
S-1/A
IPO registration (amended)
22 Sep 23
S-1/A
IPO registration (amended)
8 Sep 23
S-1
IPO registration
29 Aug 23
Other
EFFECT
Notice of effectiveness
19 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
UPLOAD
Letter from SEC
16 Jan 24
EFFECT
Notice of effectiveness
26 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
CORRESP
Correspondence with SEC
25 Sep 23
CORRESP
Correspondence with SEC
22 Sep 23
Ownership
SC 13G/A
Medarova Zdravka
15 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Lind Global Fund II LP
7 Dec 23
SC 13D/A
Dudley Robert Michael
10 Oct 23
4
Thomas A Fitzgerald
2 Oct 23
4
Robert Michael Dudley
2 Oct 23
SC 13G
TANG CAPITAL PARTNERS LP
26 Sep 23
4
Robert Michael Dudley
22 Jun 23
SC 13D/A
Dudley Robert Michael
16 Jun 23